Matt Hoffman

Get caught up on some of the latest news in Alzheimer disease and dementia, with data updates and expert insights, all in one place from the NeurologyLive® team.

The oral suspension, marked as Ztalmy by developer Marinus, is the first drug approval for cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (also known as CDD), given the greenlight in March. The agent is now available as of July 28, 2022.

Those with an optimal Life's Simple 7 score had roughly a 30% to 43% lower lifetime stroke risk than those with an inadequate Life's Simple 7 categorization, corresponding to almost 6 additional years of stroke-free life.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Get caught up on some of the latest news in headache and migraine, with data updates and expert insights, all in one place from the NeurologyLive® team.

The Rapid Hyperdensity tool uses noncontrast CT scans to evaluate the hyperdense tissue volume during the identification and assessment of intracerebral hemorrhage.

Expected to be marketed as Lumryz by Avadel Pharmaceuticals, the extended-release oral suspension sodium oxybate’s final approval is pending the disposition of the REMS patent listed in the FDA’s Orange Book.

Jill Farmer, DO, MPH, director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute, spoke at length about the recent ATMRD Congress, the state of care for movement disorders, and her hopes for the horizon of therapy and treatment.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Rajesh Pahwa, MD. [LISTEN TIME: 27 minutes]

Get caught up on some of the latest news in epilepsy and seizure disorders, with data updates and expert insights, all in one place from the NeurologyLive® team.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

After 3 instances of clinically significant, transient hypotension—which resolved after treatment halt—recruitment for the trial of the investigational recombinant KLK1 tissue protein has been paused.

Those with the common thyroid disorder displayed a more than 80% increased risk of dementia, with a more than 3-fold increase in the risk among those requiring hormone replacement therapy.

Get caught up on some of the latest news in movement disorders, with data updates and expert insights, all in one place from the NeurologyLive® team.

Expert clinicians offer their insight on the sleep disorder landscape, the state of mental health in pediatric migraine, an inaugural movement disorders congress, a novel stroke rehabilitation tool, and psychedelics in cluster headache.

Rachel Alvarez and Gustavo Dziewczapolski, PhD, of Cure CMD spoke about the benefits of attending the biennial Scientific & Family Conference to learn more about congenital muscle diseases and interact with the patient community.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Serena L. Orr, MD, MSc. [LISTEN TIME: 32 minutes]

Jean Hubble, MD, semi-retired neurologist and consultant, spoke with the PMD Alliance at the ATMRD Congress about the advances made in the field and her hopes for the future of therapeutics and clinical care.

The NeurologyLive® team assembled some of the best discussions with leaders in headache and migraine medicine following the 2022 American Headache Society (AHS) Annual Scientific Meeting.

Among a large cohort of outpatient and inpatient individuals, the risk of Alzheimer disease, Parkinson disease, ischemic stroke, and intracerebral hemorrhage were all elevated after infection, with stroke risk increased compared with other respiratory infections.

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

The trial was terminated because of the expectation of enrollment not being feasible, driven by the recent CMS national coverage determination. The phase 4 confirmatory ENVISION trial is still ongoing.

Bradford C. Sippy, the chief executive officer of Tremeau Pharmaceuticals, spoke about the company’s work to reformulate rofecoxib, known now as TRM-201, to treat acute migraine.

After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.

The pharmacodynamic and pharmacokinetic effects of the novel Amneal Pharmaceuticals therapy suggest that it can overcome the current absorption and exposure limitations of the oral levodopa therapies used to treat those with Parkinson disease motor fluctuations.

In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.